<DOC>
	<DOC>NCT00273442</DOC>
	<brief_summary>To assess the safety and efficacy of a cohort of patients switched to the dorzolamide/timolol maleate fixed combination because they are insufficiently controlled on latanoprost monotherapy.</brief_summary>
	<brief_title>Assessing Cosopt Switch Patients</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Exfoliation Syndrome</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Dorzolamide</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>adults with clinical diagnosis of POAG, pigmentdispersion or exfoliation glaucoma or ocular hypertension the IOP on latanoprost must be 31 mm Hg or less in both eyes, and 21 to 31 mm Hg inclusive in at least one eye at 08:00 AM visual acuity should be 20/200 or better in each eye contraindications to study drugs anticipated change in systemic hypotensive therapy during the trial use of any corticosteroids by any route in the three months immediately prior to Visit 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>